Navath Suryakiran, Rao Venkataramanarao, Woodford Rita-Marie T, Midura-Kiela Monica T, Ahad Ali M, Alleti Ramesh, Kiela Pawel R, Mash Eugene A
Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721.
ACS Med Chem Lett. 2012 Sep 13;3(9):710-714. doi: 10.1021/ml300086c. Epub 2012 Aug 1.
A molecular scaffold bearing eight terminal alkyne groups was synthesized from sucrose. Eight copies of an azide-terminated, azo-linked precursor to 5-aminosalicylic acid were attached to the scaffold via copper(I)-catalyzed azide-alkyne cycloaddition. The resulting compound was evaluated in a DSS model of colitis in BALB/c mice against sulfasalazine as a control. Two independent studies verified that the novel pro-drug, administered in a dose calculated to result in an equimolar 5-ASA yield, outperformed sulfasalazine in terms of protection from mucosal inflammation and T cell activation. A separate study established that 5-ASA appeared in feces produced 24-48 hours following administration of the pro-drug. Thus, a new, orally administered pro-drug form of 5-aminosalicylic acid has been developed and successfully demonstrated.
从蔗糖合成了一种带有八个末端炔基的分子支架。通过铜(I)催化的叠氮化物-炔烃环加成反应,将八个叠氮化物末端、偶氮连接的5-氨基水杨酸前体连接到该支架上。在BALB/c小鼠的结肠炎DSS模型中,以柳氮磺胺吡啶作为对照,对所得化合物进行了评估。两项独立研究证实,以计算得出能产生等摩尔5-ASA产量的剂量给药的新型前药,在预防黏膜炎症和T细胞活化方面优于柳氮磺胺吡啶。另一项研究表明,在前药给药后24-48小时产生的粪便中出现了5-ASA。因此,已开发并成功证明了一种新的口服5-氨基水杨酸前药形式。